# Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

> **NCT04803318** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

## Key facts

- **NCT ID:** NCT04803318
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2037-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803318, "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04803318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*